Amelioration of lipophilic compounds in regards to bioavailability as self-emulsifying drug delivery system (SEDDS)

Pragya Baghel1*, Amit Roy1, Shekhar Verma2, Trilochan Satapathy3 and Sanjib Bahadur1

Abstract

Background: High lipophilicity and poor aqueous solubility are the endemic problems of new drug molecules. Sixty to seventy percent of these drugs are unable to solubilize completely in aqueous media, or have very low permeability. This hampers their oral absorption and further leads to their poor bioavailability. Various researches are in progress to overcome these limitations. Novel technologies like nano-carrier systems have become popular for improving the solubility of drugs.

Main body: Lipid-based formulations, among nano systems, are taking pace for the enhancement of solubility, oral absorption, and hence the bioavailability of drugs. Among the lipid formulations, self-emulsification systems are gaining popularity by offering various advantages to delivery systems. Self-emulsifying drug delivery systems (SEDDS) are isotropic blends of oil and surfactant/co-surfactants. These ingredients upon gentle agitation in aqueous media results in the formation of o/w emulsion. In spite of many works published in SEDDS, the major concerns of this article are to discuss the various approaches to formulate a good lipid-based carrier system for poorly aqueous soluble drugs, role of various polymers, and their categories used in the formulation along-with the modern technologies used for enhancing the stability of liquid SEDDS. This review majorly focuses upon the problems related to the poor aqueous solubility of the newer lipid molecules and the solutions to overcome their solubility and in addition bioavailability.

Conclusion: As per the researches done in formulation and optimization of SEDDS for the enhancement of bioavailability of lipophilic molecules, it can be stated that the aqueous solubility as well as bioavailability can be increased by many folds compared to their marketed or other oral formulations.

Keywords: Dispersion system, Lipophilicity, Self-emulsification, Nano-carrier, Bioavailability

Background

The medications are commonly administered orally; however, around 40% of new drug competitors have poor-water solvency and the oral delivery of such medications is troublesome in view of their low bioavailability, high intra- and inter-subject fluctuation, and an absence of dose proportionality [1, 2]. Low aqueous solvency is the significant issue experienced with development of new chemical compounds [3–5]. Restricted aqueous dissolvability and high lipophilicity confine the remedial result for all medications [1]. It is advisable to broaden the therapeutic efficacy of medications by expanding the bioavailability of the medication and additionally by reducing interpatient changeability in plasma level concentration [4–6]. The most important factor for drugs administered orally is their solubility [2]. The desired concentration of any drug to achieve its pharmacological response is based on this factor majorly and thus it is most challenging for formulation scientists to maintain the pharmacological range of such poorly

* Correspondence: pragyabaghel88@gmail.com
1Columbia Institute of Pharmacy, Vil.-Tekari, Near Vidhan Sabha, Raipur, Chhattisgarh, India
Full list of author information is available at the end of the article
aqueous soluble drugs [1]. Poor aqueous solubility and low dissolution rate are the major cause of inadequate oral bioavailability of lipophilic drugs [4, 5, 7].

To overcome these issues, various strategies are opted including the use of surfactants, lipids, permeation enhancers, micronization, salt formation, cyclodextrin complexation, nanoparticles, and solid dispersions [8, 9]. Various factors influence the oral bioavailability, such as aqueous solubility, drug permeability, dissolution rate, first-pass metabolism, presystemic metabolism, and susceptibility to efflux mechanisms [10]. Lipid soluble drugs require higher doses to reach therapeutic plasma concentrations following oral administration [11]. An enhancement in the solubility and dissolution rate can enhance the oral bioavailability of such compounds, which in addition improves the healing efficacy and patient compliance [12]. This can be beneficial in lowering of frequent dosing of the drugs, required to obtain the identical/extended degree of bioavailability determined with a traditional formula. This would enhance predictability of the remedy and increase uniformity of treatment in patient population [8].

Lipinski’s rule of five has gained a valued importance as qualitative predictive model for the estimation of absorption of poorly absorbed drug molecules. In his finding, it was stated that “the rule of 5” predicts that poor absorption or permeation is more probable when there are more than 5H-bond donors, 10H-bond acceptors, the molecular weight is greater than 500, and the calculated Log P is greater than 5. This rule is effective for the drugs that are not substrates for active transporters and efflux mechanisms [15].

**Main text**

It is possible to enhance the oral bioavailability and reduce the probable side effects of an active pharmaceutical ingredient with lipid-based carrier systems. Lipid-based carriers are less toxic compared to other delivery systems, as they are biocompatible and biodegradable [16].

**Solubility**

Enhancement of solubility thereby oral bioavailability of such drug molecule remains one of the most difficult aspects of the drug development process especially for oral-drug delivery system [17]. Various approaches are stated in literatures and are available for the enhancement of solubility of poorly aqueous soluble drugs, especially when administered orally. These approaches are opted based on certain aspects, such as properties of drug under consideration, nature of excipients to be selected, and nature of intended dosage form. In addition, modification of crystal habit, reduction of particle size, solid dispersions, solid solutions, salt formation, and miscellaneous methods, including supercritical fluid process and use of surfactant, solubilizers, cosolvency, hydrotropy, and novel excipients as adjuvant to increase solubility are considered [18]. In practice, the occurrence of spontaneous emulsification is difficult to establish because when mechanical agitation is absent gravitational force provides a small quantity of energy for emulsification. The ratio and overall concentration of oils and surfactants in each formulation will determine the rate and extent of the absorption of any drug [19]. To enhance the rate of absorption, digestibility of oil and partition of the drug between the two phases should be optimized. The principal concept of lipid-based drug delivery system is to bring the drug in its dissolved state, by the formation of its colloidal dispersion in the gastrointestinal tract. This dispersion helps to enhance the solubility and absorption of lipophilic drugs in aqueous system. Various forms of lipid-based delivery systems are present, namely solutions, suspensions, emulsions, microemulsions, SEDDS, or dry emulsions [20].

**Theory of Pouton**

In the year 2000, Pouton introduced one useful lipid formulation classification system (LFCS). LFCS was recreated in the year 2006 by Pouton himself. As per the LFCS, SEDDS (type II) is an isotropic mixture of oil or mixture of oils and surfactant/s and on exposure to the gastric media; it gets emulsified [21]. Therefore, it can be said that the self-emulsifying systems improves the absorption and distribution of drug by avoiding the slow dissolution and gastric irritation, leading to improved bioavailability of lipid-soluble drugs. Ability to dissolve the poorly aqueous drugs in suitable solvents, thereby enhancing their absorption and bioavailability, is the major reason behind the growing demand of lipidic excipients [22].

**Lipid-based drug delivery system classification by Pouton**

Pouton classified the lipid-based delivery system for poor aqueous soluble drugs into four categories, as described in the table below (Table 1).

Various in-vivo properties of lipid-based delivery systems associated with their bioavailability enhancing property include the following:
Table 1 Classification of LBDDS by Pouton

| Category   | OIL (lipophilic) | Surfactant (lipophilic) | Surfactant (hydrophilic) | Co-solvents | Formulations                  |
|------------|------------------|-------------------------|--------------------------|-------------|--------------------------------|
| Category I | 100 %            | 0%                      | 0%                       | 0%          | Simple oily solutions         |
| Category II| 40-80%           | 20-60%                  | 0%                       | 0%          | SEDDS                         |
| Category III| 0%               | 20-40%                  | 20-40%                   | 20-50%      | SMEDDS                        |
| Category IV| 0%               | 0-20%                   | 20-80%                   | 0-80%       | Colloidal micellar dispersions|

SEDDS self-emulsifying drug delivery systems, SMEDDS self-micro-emulsifying drug delivery systems [23]

1. Prevention of drug precipitation and recrystallization by the formation of fine dispersion and micellar suspension
2. Improved drug absorption by implying certain changes in GIT by the lipid compounds and its metabolites
3. This system has the ability to inhibit the efflux system, which fluctuates the distribution of drug. Controlled efflux system controls the drug circulation in the cellular system.
4. Helps reduce the first-pass drug metabolism by the mechanism of drug uptake directly into the lymphatic transport [24].

Digestion and absorption are the two complex mechanisms, which are yet to be understood well by the scientists. However, lipid excipients provide a safe and effective way of formulating a lipophilic drug with enhanced solubility and bioavailability. In addition to the solubility and bioavailability, this system introduces various improved chemical and mechanical technologies to deal with such problems [1, 4, 5].

Self-emulsifying drug delivery systems

As per the known definitions, SEDDS are isotropic mixtures of natural/synthetic oils, solid/liquid surfactants, and/or one or more hydrophilic solvents and co-solvents/surfactants [25]. Again, as stated earlier, with a mild agitation they dilute the drug in the system (aqueous media), such as GI fluids, and forms fine oil-in-water (o/w) emulsions (0.1-100 μm) or microemulsions (10-300 nm), spreading readily into the GIT where agitation is provided by the movement of the stomach and intestinal fluid forming a self-emulsified system [26]. Figure 1 represents an illustrative diagram explaining the mechanism of self-emulsification.

SEDDS are modified further as self-micro emulsifying drug delivery systems (SMEDDS) or self-nanoemulsifying drug delivery systems (SNEDDS) drug delivery systems, classified as type IIIa or IIIb, respectively [27]. This modified form additionally contains one or more co-surfactant or co-solvents (hydrophilic) [28]. By the application of ternary phase diagram, and modifying the rations of oil/surfactant, SEDDS can be prepared experimentally, using the “trial–error” method [29].

![Fig. 1 Mechanism of self-emulsification](image-url)
Advantages
Potential advantages of these systems (SEDDS) include the following:

1. Dose reduction by ability to improve the solubility
2. More steady chronological profiles of drug absorption
3. Specific absorption from targeted area
4. Drug protection from the unstable GIT surroundings
5. Control of delivery profiles
6. Reduction in variable drug action
7. Protection of susceptible drug substances
8. Enhanced drug potential
9. Available in both liquid and solid dosage forms
10. No/less, influence of lipid digestion on SEDDS
11. Drug dose can be reduced by these formulations.
12. Easy manufacturing and scaling up technique is used.
13. This formulation provides quick onset of action [29, 30].

Suitable drug candidates for SEDDS
Although SEDDS is suitable for all the four categories of BCS classification system, but the candidates that are required to be formulated as SEDDS fall under BCS class II and IV categories [31].

Application of SEDDS in drug solubility and dissolution

1. SEDDS aids in the incorporation of active pharmaceutical ingredients (API’s) in a lipid vehicle imparting improved drug dissolution in an aqueous medium.
2. Improved drug dissolution affects the drug release and GI-absorption.
3. In addition, drug can easily penetrate into the surfactant interfacial layer, which enhances its penetration through membrane barriers and its efficacy [32].

Applications of self-nanoemulsifying drug delivery system and its novel approaches

1. Various novel advancements in SNEDDS include solid SNEDDS, super saturated SNEDDS, self-double emulsions (w/o/w), controlled release SNEDDS, SNEDDS for overcoming mucus gel barrier, delivery of biomolecules, and even drug targeting.
2. Super saturated SNEDDS include hydrophobic precipitation inhibitors that control drug precipitation, during storage, hence improving its stability.
3. Solidification of liquid SNEDDS (L-SNEDDS) inhibits the interaction of drug and excipients, interaction of liquid dosage with the capsule shell, etc.
4. Biomolecules with low bioavailability can be designed easily using SEDDS, as they provide small droplet size and maximum surface area for the better penetration of molecules.
5. Other advancements like targeted SNEDDS, self-double SEDDS have also gained popularity in increasing the solubility, bioavailability, and stability of molecules [33].

Dosage forms of SEDDS
Various dosage forms, such as capsules, sustained release, and controlled release tablets/pellets, dispersion systems can be easily formulated using self-emulsified dosage design. SEDDS is also suitable for other routes other than oral, like topical, ocular, pulmonary, and parenteral route [34].

Composition of self-emulsifying drug delivery systems
Self-emulsification process depends upon the following:

1. Nature and ratio of oils and surfactants
2. Concentration of surfactant
3. Temperature and time of self-emulsification [35]

Excipients used in the formulation of SEDDS

Oils
The most important and basic ingredient of SEDDS are oils, as they have the ability to dissolve lipid molecules and improve their solubility [36]. Depending upon the nature of triglycerides, drug transportation of the lipid drug is increased, via the lymphatic system. In addition, GIT absorption of the drug is also increased [37]. Generally, long and medium-chain triglycerides (LCT and MCT) are preferred for the formulation of SEDDS. The LCT and MCT are used with different degrees of saturation [38]. Dietary lipids undergo lipolysis, and are converted to monoglycerides and free fatty acids. Short-chain triglycerides (SCT) and MCT get absorbed quickly and reach the systemic circulation as soluble fatty acids. Whereas a different absorption is found for the LCT, as they get absorbed they esterify and forms chylomicrons. Triglycerides, apoproteins, cholesterol, and cholesterol ester comprises the chylomicrons. They are absorbed through the lymphatic uptake. This serves as a vehicle system here, for various lipophilic molecules, bypassing the liver [39].

List of oils used in the formulation of SEDDS/SMEDDS/SNEDDS:

1. Glyceryl monolinoleate
Surfactants
Surfactants are having amphiphilic character. They help in the solubilization of lipophilic drug compounds. In the gastrointestinal lumen, this prevents precipitation of drug [40]. Hence, drug sustains in the GIL for a definitely longer time [32]. For the formulation of SEDDS, various compounds having surfactant properties can be used, but those having oral acceptance should be chosen [41]. Surfactants are of four types, namely cationic (quaternary ammonium halide), anionic (potassium laureate, sodium lauryl sulfate), ampholytic (sulfobetaines), and non-ionic surfactants [sorbitan esters (spans), polysorbates (tweens)] [42]. Among all the surfactants, the most preferable ones are the non-ionic surfactants, having relatively high hydrophilic-lipophilic balance (HLB) [43]. Optimum concentration of surfactants, for the formulation of a stable SEDDS is 30-60% [35, 44–46].

Surfactants are grouped as follows:

- Anionic surfactants
- Cationic surfactant
- Ampholytic surfactants
- Non-ionic surfactants
  (a) Anionic surfactants—in this class, the hydrophilic group carries a negative charge, for example, carboxyl (RCOO-), sulfonate (RSO3-), or sulfate (ROSO3-).
  (b) Cationic surfactants—in this class, the hydrophilic group carries a positive charge.
  (c) Ampholytic surfactants—(also called zwitterionic surfactants) contain both a negative and a positive charge.
  (d) Non-ionic surfactants—in this class, the hydrophilic group carries no charge but imparts water solubility from its polar groups such as hydroxyl or polyoxyethylene (Tweens) [44].

Biosurfactants
Surfactants may alter the therapeutic efficacy of the drug molecule, as its concentration may vary and as a result may hamper the availability of the drug at the absorption site. It may also produce some toxicity at various concentrations. This can be overcome by the use of biosurfactants in place of normal surfactants. Biosurfactants increase the safety and decrease toxicity associated with the gastric irritation caused by the surfactants [47].

Co-solvents
Organic solvents are one of the best options to be used as co-solvents for SEDDS, such as ethanol, propylene glycol, and polyethylene glycol, this aid in the increased solubility of lipid drugs [5]. Higher concentrations of surfactant are required for the optimum formulation of SEDDS, but this higher concentration may lead to the drug precipitation [48]. Therefore, co-solvents are added to lower the surfactant concentration and maintain the uniformity of the formulation [4, 49].

Co-surfactant
In addition to co-surfactant, the concentration of surfactants can be decreased, as it increases the loading capacity of the active pharmaceutical compound. Co-surfactants increase the interfacial fluidity and hence reduce the chances of variability and local irritation caused by surfactants also enhancing the process of dispersion in the medium [50]. Ethanol, propylene glycol, and other newer co-surfactants such as transcutol P and Glycofurol are a few of common excipients used as co-surfactants [51].

Some examples of co-surfactants and co-solvents:

1. Mixture of glycerol an ethanol
2. Transcutol
3. Capmul MCM
4. Glycerol
5. Polyethylene glycol
6. PEG 400
7. Glycofurol

Newer components of formulation in SEDDS and SMEDDS
SEDDS and SMEDDS have gained popularity among other nanoparticle dosage forms in many ways. Further modifications on SEDDS and SMEDDS are done by including some more new components that can enhance drug absorption. However, the selection of these components largely depends on the proper ratio of the mixture of oil and surfactant along with the co-surfactant and co-solvents. Still, some modifications have been made for the enhancement and stability of such formulations. These include the inclusion of adsorbents like silica gel and neusilin to solidify the liquid formulation. Grafted polymers are being use as modifiers such as, aeroperl and soluplus. Along with the components, various techniques are being adopted for improving the stability and efficacy of these dosage forms [52].
Role of polymers in SEDDS and SMEDDS formulation
The below Table 2 summarizes a few of polymers along with few excipients which plays different roles in the design and optimization of SEDDS and SMEDDS.

Importance of emulsion droplet size on drug absorption
Globule size of the particles in microemulsion is the factor affecting the bioavailability at different levels [55]. It has been stated that dispersion at nano-scale affects the rate of drug absorption, but it cannot be said exactly that lower droplet size will enhance the bioavailability of the drugs [56]. Yap and Yuen stated that bioavailability of tocotrienol SEDDS from two microemulsions, one of which is very prone to lipolysis while another with minor emulsion globule range, showed similar results, regardless of the droplet size [57].

Challenges of using S-SMEDS in food and pharmaceutical industries
In order to lower the surface tension between the two phases, higher concentrations of surfactant and co-surfactant are required, this may lead to the increase in toxicity [58]. Although the cytotoxicity of surfactants, which are generally used in food and pharmaceutical systems, has been widely studied, little is known about the toxicity of surfactants in microemulsions and especially in solid self-emulsifying drug delivery systems (SSMEDDS). Some studies reported that the toxicity of a surfactant would change in these systems [59]. For example, Warisnoicharoen et al. established a fact that using Brij97 (polyoxyethylene-10-oleyl ether) alone or in a combined form with low molecular weight (LMW) oils was toxic over a range above its critical aggregation concentration [60]. However, a combination of Brij97 with high molecular weight oils (e.g., Miglyol 812 and soybean oil) was observed to be toxic only at levels higher than the critical aggregation concentration [5, 61]. The formation of a distinct oil core in the aggregates, which resulted in lowering the ability of the system to solubilize the cell membrane components, was suggested to be the reason of reducing the toxicity of the high molecular weight oil microemulsions. Some researchers and scientists found that the cell toxicity of single components of vitamin E microemulsions (e.g., El-35 and ethyl butyrate) was higher than that of the microemulsions [62]. Some researchers and scientists evaluated the cytotoxicity of β-carotene microemulsions prepared from Tween 80 and medium-chain triglycerides (Capmul MCM) [46]. An increase in toxicity was observed at concentration higher than 0.0313% when Tween 80 interacted with the cell culture monolayer [63]. According to the recent research, it was found that microemulsions and SEDDS formulation of atrovastatin was cytotoxic, with the use of isopropyl myristate, a combination of 2 biocompatible surfactants: lecithin/D-α-tocopheryl polyethylene glycol succinate (TPGS) and ethanol as cosurfactant [64]. The S-SMEDDS formulations prepared with lecithin-20 had highest in vitro cytotoxicity and lowest IC50 than those prepared with lecithin-100 [65].

Enhancement of stability through SEDDS and SMEDDS
With the formulation of SEDDS and SMEDDS, researchers have found that the formulation design is optimum for the lipophilic drugs. Enhancement of oral solubility and bioavailability is proven parameters for these systems. However, there are some drawbacks like physical stability and pharmacokinetics of the formulation system, which has to be overcome. Certain modifications have been made regarding the issues raised. One of which is the formation of the liquid preconcentrate to its solid form. Liquid solid compacts are one such modifications, these are a mixture of liquid preconcentrate

| Table 2 Role of polymers |
|--------------------------|
| **S. no** | Polymer used | Role of polymer | Reference |
| 1. | Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®) and Aeroperl® 300 Pharma | Formation of spray-dried solid dispersion | [52] |
| 2. | Stearic acid phosphotyrosine | Zeta potential modifier in SEDDS | [53] |
| 3. | Polyvinylpyrrolidone (PVP) VA64 and sodiumdodecyl sulfate (SDS) | Combined stabilizers | [16] |
| 4. | Soluplus® mixed with D-α-tocopheryl polyethylene glycol-1000-succinate (TPGS) | Formation of micelles for improved stability and bioavailability | [14] |
| 5. | Soluplus | Supersaturation stabilizer | [27] |
| 6. | Neusilin US2® - (excipient) | Solidification | [43] |
| 7. | Precipitated papain | Mucus permeation enhancer | [42] |
| 8. | Fujicalin (dibasic calcium phosphate) - (excipient) | Porous carrier as adsorbent | [54] |
| Drug            | Oils                        | Surfactant/co-surfactant                          | Formulation type                                      | Therapeutic outcome                                    | Ref. |
|-----------------|-----------------------------|---------------------------------------------------|------------------------------------------------------|--------------------------------------------------------|------|
| Silybin         | Labrafac                    | Cremophore RH40/transcutol                        | Supersaturatable self-emulsifying drug delivery system (S-SEDDS) | Enhanced oral bioavailability                           | [6]  |
| Fenofibrate     | Medium-chain triglyceride oil (Myritol 318), TPGS (D-a-tocopherol polyethylene glycol 1000 succinate) and polysorbate (Twee 80 or Tween 20) | Labrafil M1944, Labrasol, OP-10/ Transcutol P | Self-microemulsifying drug delivery system (SMEDDS) | Increased oral bioavailability                         | [13] |
| Rosuvastatin calcium | Capmul MCM                 | Cremophore ELP/Propylene Glycol                   | Solid self-emulsifying drug delivery system          | Improved bioavailability                               | [19] |
| Celastrol       | Corn oil, soybean oil, ethyl oleate, GTCC, IPM, castor oil, maize-1, olive oil, IPP | Labrafil 7104, Labrasol, OP-10/Transcutol P | Solid self-microemulsifying dispersible tablets      | Increased bioavailability                              | [26] |
| Alginate and curcumin | Cremophor EL, Larafac PG, Capryol 90 | Labrasol, Sodium CMC (absorbent), Aerosil 200 | Curcumin loaded solid SMEDDS designed by freeze-drying technique | Enhance the release profile of drug                   | [28] |
| Dutasteride     | Capryol 90                  | Cremophore EL/transcutol HP                        | Gelatin microparticles of a self-emulsified system   | Improved oral bioavailability of dutasteride           | [34] |
| Dutasteride     | Capryol 90                  | Cremophore EL/Transcutol HP                       | Soluplus-based supersaturable self-emulsifying drug delivery system | Improved oral absorption of dutasteride               | [35] |
| Carbamazepine   | Caprylic/ Capric triglycerides | Polysorbate 80/cremophore-RH40                    | Solid self-microemulsifying drug delivery systems | Improved drug release and increase bioavailability | [45] |
| ELQ – 331       | Tween-20, Span® 85, PEG 400 and sodium lauryl sulfate | Tween-20, Span® 85, PEG 400 | Preparation of spray dried dispersions and its comparison | Described the effect on the solubility and bioavailability of produg | [52] |
| Glyburide       | Capryol 90, Lauroglycol 90, Labrafac Hydro WL 1219, polyglyceryl-3 dioleate | Labrasol, Tween 20/glycofurol, transcutol, PEG 400 | fast-dissolving solid self-microemulsifying tablets | Improve dissolution and technological properties       | [58] |
| Ritonavir       | Invitor 988                 | Cremophore EL and cremophore RH 40 (1:1)/capmul GMS K-50 | Solid self-microemulsifying drug delivery system | Enhance dissolution and oral bioavailability of drug | [67] |
| Simvastatin     | Capryol 90                  | Kolliphor EL/transcutol P                         | Self-emulsifying drug delivery system                | Improved drug release                                  | [68] |
| Carbamazepine   | Myglol 812                  | Cremophor EL/macrogol 400                         | Solid self-microemulsifying drug delivery systems (S-SMEDDS) | Increase in dissolution rate compared to pure Carbamazepine | [69] |
| Naproxen        | Miglyol 812                 | Gelucire 44/14                                    | Tablets and mini-tablets of spray dried SMEDDS      | Lowered dissolution profile of naproxen from tablets and minitablets | [70] |
| Atorvastatin    | Oleic acid and capryol 90   | Caprol MPG, Kolliphor RH40, Labrasol and Tween 80/PEG 400 and 1,2-propylene glycol | Liquid and solid Self-Emulsifying Drug Delivery Systems | better solubilization properties exhibited by solid formulation | [71] |
| Atonvastatin    | Isopropyl myristate         | lecithin/D-a-tocopherol polyethylene glycol succinate/ethanol | Spray-dried self-microemulsifying drug delivery systems | Enhanced the cytotoxic activity on lung cancer cells | [72] |
| Paprika Oleoresin (carotenoid) | Limonene                   | Tween 80/ethanol                                  | Solid self-microemulsifying system                   | Enhanced bioavailability and pigmentation              | [73] |
| Naproxen        | Miglyol 812                 | Gelucire 44/14/glycerin                           | Solid SMEDDS                                         | Preserved the self-microemulsifying properties of liquid SMEDDS & exhibited dissolution profiles similar to liquid SMEDDS | [74] |
| Atonvastatin    | Coconut oil and isopropyl myristate | Tween 80/PEG 400 and glycerin                    | Solid self-micro emulsification system               | Improve bioavailability                               | [75] |
with a non-volatile solvent, further converted to a solid form by adsorption to a solid carrier. This is a simple and advanced technique to enhance the stability of liquid SEDDS, bypassing its instability in liquid state [66].

Table 3 includes a detailed study of drugs formulated as liquid/solid SMEDDS and their therapeutic outcomes, and Table 4 includes a detailed study of drugs formulated as liquid/solid SNEDDS and their therapeutic outcomes.

### Table 3 List of drugs formulated as solid/liquid self-micro emulsified drug delivery systems (SMEDDS) (Continued)

| Drug                    | Oils                                                                 | Surfactant/co-surfactant | Formulation type                                      | Therapeutic outcome                                      | Ref. |
|-------------------------|----------------------------------------------------------------------|--------------------------|-------------------------------------------------------|----------------------------------------------------------|------|
| Mefanamic Acid          | clove oil, olive oil and rice bran oil, Imwitor 742                   | Tween 60, cremophore El/Transcutol HP | Self-emulsifying formulation                           | Enhance solubility                                        | [76] |
| Atrovastatin calcium    | Capmul* MCM                                                           | Tween* 20/tetraglycol    | Solidified self-microemulsifying drug delivery system | Improve dissolution and bioavailability                   | [77] |
| Mebendazole             | Labrafil 2125 CS                                                     | Tween 20/maisine 35-1    | Self-microemulsifying drug delivery System             | Improve dissolution and bioavailability                   | [78] |
| Huperzin                | Cremophor RH40                                                       | Propylene glycol         | Self-microemulsifying drug delivery system             | Enhancing bioavailability and lymphatic uptake of the drug | [79] |
| Curcumin                | Caprylic acid, cremophor RH 40, cremophor EL                         | Tween 80 and PEG 200     | Vaginal self-emulsifying delivery system               | Enhancement of drug penetration                           | [80] |
| Cathepsin K inhibitor (HL235) | Capmul MCM EP                                                   | Tween 20 (surfactant) and 20.0% carbitol (cosurfactant) | SEDDS were prepared by applying D-optimal mixture design | Improve drug solubility and drug loading. Increase bioavailability | [81] |
| Ferulic acid            | Glyceryl triacetate, OP-10, Labrasol combination                     | PEG 400                  | Preparation of SMEDDS for                              | Enhancement of oral solubility of drug with improved hypnotic activity | [82] |
| Kaempferol and quercetin from plant Moringa oleifera | CrodamoTM P C (propylene glycol dicaprylocaprate) | Tween* 80 and polyethylene glycol 400 | SMEDDS                                                 | Enhancement of solubility of the flavonoids              | [83] |
| Nilotinib               | Capryol 90                                                           | Transcutol HP and Tween 80 | SMEDDS                                                 | Enhancement of solubility of the drug                     | [84] |

### Table 4 List of drugs formulated as solid/liquid self-nano emulsified drug delivery systems (SNEDDS)

| Drug                        | Oils                                                                 | Surfactant/co-surfactant | Formulation type                                      | Therapeutic outcome                                      | Ref. |
|-----------------------------|----------------------------------------------------------------------|--------------------------|-------------------------------------------------------|----------------------------------------------------------|------|
| Naringenin                 | Triacetin                                                            | Tween 80/Transcutol P    | Self-nanoemulsifying drug delivery system             | Improve oral bioavailability                              | [1]  |
| Talinolol                   | Triacetin, Miglyol 812, castor oil, isopropyl myristate, soybean oil, and olive oil | Span 20, Span 80, Labrafac PG, Plurrol Oleique, and Lauroglycol 90/ethanol, PEG 200, PEG 400, propylene glycol | Self-nanoemulsifying drug delivery system (SNEDDS) | Improved permeability of drug                              | [7]  |
| Glyburide                   | Miglyol 812, Ethyl oleate                                            | Tween 80, Cremophore RH 40/1,2-pranapanediol, PEG 400 | Self-nanoemulsifying drug delivery system             | Improved oral bioavailability                              | [20] |
| Atazanavir                  | Maisine 35-1                                                         | Transcutol P and Span 20 | Self-nanoemulsifying drug delivery system             | Enhance oral bioavailability                              | [29] |
| β-carotene                  | Corn oil, orange oil                                                 | Tween 80                 | Nanoemulsion-based delivery systems formed by spontaneous emulsification | β-carotene bioaccessibility increased due to greater solubilization in mixed micelles | [85] |
| Resveratrol                 | Imwitor                                                              | Transcutol, Tween 80     | Nanoemulsion-based delivery systems formed by spontaneous emulsification | Developed a method which can measure the emulsification of SEDDS | [86] |

### Conclusion

As stated in the literature and with a brief review, it can be now said that SEDDS is a better approach for the formulation and development of delivery systems for low solubility and/or low permeability drugs, to facilitate their dissolution and absorption. The process of manufacturing is excellent and simple and with the use of conventional and commonly available equipments.
Abbreviations
SEDDS: Self-emulsifying drug delivery systems; GIT: Gastrointestinal tract; LFCs: Lipid formulation classification; SMEDDS: Self-microemulsifying drug delivery systems; SNEDDS: Self-nanoemulsifying drug delivery systems; BCS: Biopharmaceutical classification system; LCT: Long chain triglycerides; MCT: Medium chain triglycerides; S-SMEDDS: Solid self-emulsifying drug delivery systems; LMW: Low molecular weight; TPGS: Tocopheryl polyethylene glycol succinate; SLN: Solid lipid nanoparticles; NLC: Nanostructured lipid carriers; HLB: Hydrophilic lipophilic balance

Acknowledgements
NA

Authors’ contributions
PB compiled and designed the final manuscript data. She collected the basic informations by literature survey and formatted the blinded manuscript as review of self-emulsifying drug delivery systems. AR checked the initially collected manuscript data. He also checked for the plagiarism of the manuscript and edited the final manuscript according to all authors' advice. All authors have read and approved the manuscript.

Funding
NA

Availability of data and materials
All data and materials are available upon request.

Ethics approval and consent to participate
NA

Consent for publication
NA

Competing interests
The authors declare that they have no competing interests.

Author details
1Columbia Institute of Pharmacy, Vil-Tekari, Near Vidhan Sabha, Raipur, Chhattisgarh, India. 2Pt. Deendayal Upadhyay Smriti Health Science and Aayush University, Raipur, Chhattisgarh, India. 3Raipur Institute of Technology, Raipur, Chhattisgarh, India.

Received: 10 January 2020 Accepted: 1 June 2020

Published online: 10 June 2020

References
1. Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J (2015) Self-nanoemulsifying drug delivery system (SEDDS) of the poorly water-soluble grapefruit flavonoid Narigenin: design, characterization, in vitro and in vivo evaluation. Drug Deliv 22:S52–S56 https://doi.org/10.3109/10717544.2013.876933
2. Morrison PW, Khutoryanskiy VV (2015) Theory and practice of supersaturable formulations for poorly soluble drugs. Ther Deliv 5:1297–1314 https://doi.org/10.4155/tde.15.92
3. Savjani KT, Gajjar AK, Savjani JK (2012) Drug solubility: importance and enhancement techniques. ISRN Pharm 2012:1–10 https://doi.org/10.5402/2012/95722
4. Kavitha K, Ranjani PV (2015) Solubility enhancement – a challenge for hydrophobic drugs. IOSR Journal of Pharmacy and Biological Sciences 10: 50–60 https://doi.org/10.9790/0308-10645060
5. Singh A, Singh V, Rawat G, Juyal D (2015) Self-emulsifying systems: a review. Asian J Pharm 9:13 https://doi.org/10.4033/0973-6398.150031
6. Wei Y, Ye X, Shang X, Peng X, Bao Q, Liu M, Guo M, Li F (2012) Enhanced oral bioavailability of silybin by a supersaturatable self-emulsifying drug delivery system (S-SEDDS). Colloids Surfaces A Physicochem Eng Asp 396: 22–28 https://doi.org/10.1016/j.colsurfa.2011.12.025
7. Ghai D, Sinha VR (2012) Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β1-adrenoreceptor blocker Talinolol. Nanomed Nanotechnol Biomed 8:618–626 https://doi.org/10.1016/j.nano.2011.08.015
8. Leonavicučė G, Bernkop-Schnürch A (2015) Self-emulsifying drug delivery systems in oral (poly)peptide drug delivery. Expert Opin Drug Deliv 12: 1703–1716 https://doi.org/10.1517/17425247.2015.1068287
9. Patel A, Sharma N, Kumar A (2012) Self-emulsifying drug delivery system: a gentle approach for drug delivery. Int J Drug Deliv 4:297–309 https://doi.org/10.1098/rstb.2006.1918
10. Nigade PM, Patil SL, Tiwari SS (2012) Self emulsifying drug delivery system (SEDDS): a review. Int J Pharm Bio Sci 2:45–52
11. Rohrer J, Zupančič O, Hetényi G, Kurpiers M, Schnurch AB (2013) Design and evaluation of SEDDS exhibiting high emulsifying properties. J Drug Deliv Sci Technol 44:366–372 https://doi.org/10.1016/j.jddst.2013.01.013
12. Parmar B, Patel U, Bhimani B, Sanghavi K (2012) SMEDDS: A dominant dosage form which improve bioavailability. Am J Pharm Res 254–72
13. Fei Y, Kostewicz ES, Sheu M, Dressman JB (2013) Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro – in vivo – in vivo approach. Eur J Pharm Biopharm 85:1274–1284 https://doi.org/10.1016/j.ejpb.2013.03.001
14. Choi J, Hyuk N, Kim D, Park J (2019) Comparison of paclitaxel solid dispersion and polymeric micelles for improved oral bioavailability and in vitro anti-cancer effects. Mater Sci Eng C 101:247–259 https://doi.org/10.1016/j.msec.2019.03.002
15. Gupta S, Kesari R, Omri A (2013) Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm 2013:1–16 https://doi.org/10.1155/2013/948943
16. Ding Z, Wang L, Xing Y, Zhao Y, Wang Z, Han J (2019) Enhanced oral bioavailability of celecoxib nanocrystalline solid dispersion based on wet media milling technique: formulation, optimization and in vitro/in vivo evaluation. Pharmacuetics 11:328–345 https://doi.org/10.3390/ pharmacutes11070328
17. Tan A, Rao S, Prestidge CA (2013) Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance. Pharm Res 30:2993–3017 https://doi.org/10.1007/s11095-013-1107-3
18. Kumar Yadav S, Pharm M, Shrivastava S, Verma S (2014) Applications of self-emulsifying drug delivery systems in novel drug delivery-a review. African J Basic Appl Sci 66–14 https://doi.org/10.5829/idosi.ajbas.2014.6.1.84248
19. Rokad V, Nagda C, Nagda D (2014) Design and evaluation of solid self-emulsifying drug delivery system of rosuvastatin calcium. J Young Pharm 6: 37–46 https://doi.org/10.5373/jyp.2014.3.7
20. Liu H, Shang K, Liu W, Leng D, Li R, Kong Y, Zhang T (2014) Improved oral bioavailability of glyburide by a self-nanoemulsifying drug delivery system. J Microencapsul 31:277–283 https://doi.org/10.3109/02652048.2013.843598
21. Savadrate S, Atipairin A, Yoon AS, Srichana T, Changsan N, Suvandecha T (2019) Formulation development of albendazole-loaded self-microemulsifying chewable tablets to enhance dissolution and bioavailability. Pharmacuetics 1:134–153 https://doi.org/10.3390/ pharmacutes11030134
22. Kollipara S, Gandhi RK (2014) Pharmacokinetic aspects and in vitro–in vivo correlation potential for lipid-based formulations. Acta Pharm Sin B 4:333–349 https://doi.org/10.1016/j.apsb.2014.09.001
23. Mahapatra AK, Murthy PN, Swadeep B, Swain RP (2014) Self-emulsifying drug delivery systems (SEDDS): an update from formulation development to therapeutic strategies. Int J PharmTech Res 6:546–568
24. Khadka P, Ro J, Kim H, Kim JT, Kim H, Cho JM, Yun G, Lee J (2014) Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci 9:304–316 https://doi.org/10.1016/j.apsb.2014.05.005
25. Nikolakakis I, Partheniadis I (2017) Self-emulsifying granules and pellets: composition and formation mechanisms for instant or controlled release. Pharmaceutics 9:1–27 https://doi.org/10.3390/pharmaceutics9040050
26. Qi X, Qin J, Ma N, Chou X, Wu Z (2014) Solid self-microemulsifying dispersible tablets of celestatic: formulation development, characterization and bioavailability evaluation. Int J Pharm 472:40–47 https://doi.org/10.1016/j.ijpb.2014.06.019
27. Quan G, Niu B, Singh V, Zhou Y, Wu CY, Pan X, Wu C (2017) Supersaturable solid self-microemulsifying drug delivery system: precipitation inhibition and bioavailability enhancement. Int J Nanomedicine 12:8801–8811 https://doi.org/10.2147/ijnn.2017.9149717
Drug Dev Ind Pharm 42:506–512 https://doi.org/10.1016/j.apsb.2017.02.002

64. Guan Q, Zhang G, Sun S, Fan H, Sun C, Zhang S (2016) Enhanced oral bioavailability of pueraria flavonones by a novel solid self-microemulsifying drug delivery system (SMEDDS) dropping pills. Biol Pharm Bull 39:672–679 https://doi.org/10.1248/bpb.b15-00864

65. Anette M (2016) Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems. Eur J Pharm Sci 108:62–70 https://doi.org/10.1016/j.ejps.2016.11.022

66. Suram D, Narala A, Veerabrahma K (2020) Development, characterization, comparative pharmacokinetic and pharmacodynamic studies of iloperidone solid SMEDDS and liquid-solid compact. Drug Dev Ind Pharm 46(4):587–596 https://doi.org/10.1080/03639045.2020.1742142

67. Deshmukh A, Kulikarni S (2014) Solid self-microemulsifying drug delivery system of ritonavir. Drug Dev Ind Pharm 40:477–487 https://doi.org/10.3109/03639045.2013.768632

68. Park JB, Choi BK, Kang CY (2015) Effects of absorbent materials on a self-emulsifying drug delivery system for a poorly water soluble drug. J Pharm Invest 45:529–539 https://doi.org/10.1007/s40005-015-0021-4

69. Krstic M, Popovic M, Dobricic V, Ilic S (2015) Influence of solid drug delivery system formulation on poorly water-soluble drug dissolution and permeability. Molecules 20:14684–14698 https://doi.org/10.3390/molecules200814684

70. Čepnjak K, Bobik AZ, Večer F, Galperlin M (2015) Tablets and minitablets prepared from spray-dried SMEDDS containing naproxen. Int J Pharm 495:336–346 https://doi.org/10.1016/j.ijpharm.2015.08.099

71. Czajkowska-Kosnik A, Szekalska M, Amelian A, Szymanska E, Winnicka K (2015) Tablets and minitablets prepared from spray-dried SMEDDS containing naproxen. Int J Pharm 495:336–346 https://doi.org/10.1016/j.ijpharm.2015.08.099

72. Čepnjak K, Bobik AZ, Večer F, Galperlin M (2015) Tablets and minitablets prepared from spray-dried SMEDDS containing naproxen. Int J Pharm 495:336–346 https://doi.org/10.1016/j.ijpharm.2015.08.099

73. Chow PY, Gue SZ, Leow SK, Goh LB (2015) Solid self-microemulsifying system (S-SMECS) for enhanced bioavailability and pigmentation of highly lipophilic bioactive carotenoid. Powder Technol 274:199–204 https://doi.org/10.1016/j.powtec.2015.01.020

74. Čepnjak K, Žvanar A, Večer F, Galperlin M (2015) Characterization of naproxen-loaded solid SMEDDSs prepared by spray drying: the effect of the polysaccharide carrier and naproxen concentration. Int J Pharm 485:249–260 https://doi.org/10.1016/j.ijpharm.2015.03.019

75. Chow PY, Gue SZ, Leow SK, Goh LB (2015) Solid self-microemulsifying system (S-SMECS) for enhanced bioavailability and pigmentation of highly lipophilic bioactive carotenoid. Powder Technol 274:199–204 https://doi.org/10.1016/j.powtec.2015.01.020

76. Park JB, Choi BK, Kang CY (2015) Effects of absorbent materials on a self-emulsifying drug delivery system for a poorly water soluble drug. J Pharm Invest 45:529–539 https://doi.org/10.1007/s40005-015-0021-4

77. Ishak RAH, Osman R (2015) Leucithin/TPGS-based spray-dried self-microemulsifying drug delivery systems: in vitro pulmonary deposition and cytotoxicity. Int J Pharm 485:249–260 https://doi.org/10.1016/j.ijpharm.2015.03.019

78. Chow PY, Gue SZ, Leow SK, Goh LB (2015) Solid self-microemulsifying system (S-SMECS) for enhanced bioavailability and pigmentation of highly lipophilic bioactive carotenoid. Powder Technol 274:199–204 https://doi.org/10.1016/j.powtec.2015.01.020

79. Čepnjak K, Žvanar A, Večer F, Galperlin M (2015) Tablets and minitablets prepared from spray-dried SMEDDS containing naproxen. Int J Pharm 495:336–346 https://doi.org/10.1016/j.ijpharm.2015.08.099

80. Čepnjak K, Bobik AZ, Večer F, Galperlin M (2015) Tablets and minitablets prepared from spray-dried SMEDDS containing naproxen. Int J Pharm 495:336–346 https://doi.org/10.1016/j.ijpharm.2015.08.099

81. Čepnjak K, Bobik AZ, Večer F, Galperlin M (2015) Tablets and minitablets prepared from spray-dried SMEDDS containing naproxen. Int J Pharm 495:336–346 https://doi.org/10.1016/j.ijpharm.2015.08.099

82. Liu CS, Chen L, Hu YN, Dai JL, Ma B, Tang QF, Tan XM (2020) Self-microemulsifying drug delivery system for improved oral delivery and hypnotic efficacy of ferulic acid. Int J Nanomedicine 15:2059–2070 https://doi.org/10.2147/ijn.204949

83. Sermkaew N, Plyuang T (2020) Self-microemulsifying drug delivery systems of Moringa oleifera extract for enhanced dissolution of kaempferol and quercetin. Acta Pharma 70:77–88 https://doi.org/10.2478/aphp-2020-0012

84. Zakkula A, Gabani BB, Jairam RK, Kiran V, Todma U, Mullangi R (2020) Preparation and optimization of nilotinib self-micro-emulsifying drug delivery systems to enhance oral bioavailability. Drug Dev Ind Pharm 46:498–504 https://doi.org/10.1080/03639045.2020.1730398

85. Zhang R, Zhang Z, Kumasani T, Khosha S, Aboolanjao KO, McClements DJ (2016) Encapsulation of β-carotene in nanoemulsion-based delivery systems formed by spontaneous emulsification: influence of lipid composition on stability and bioaccessibility. Food Biophys 11:154–164 https://doi.org/10.1007/s11483-016-9426-7

86. Vanconcelos T, Marques S, Sarmento B (2018) Measuring the emulsification dynamics and stability of self-micro-emulsifying drug delivery systems. Eur J Pharm Biopharm 123:1–8 https://doi.org/10.1016/j.ejpb.2017.11.003

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.